# Exploring the Treatment of Cinnamomum Cassia Leaf Extract in Ulcerative Colitis: Network Pharmacology and In Vitro Investigations

**Authors:** Zhuoya Zhang, Junrong Guo, Zurun Huang, Xiuyan Zheng, Ping Xiong

PMC · DOI: 10.3390/plants15050706 · Plants · 2026-02-26

## TL;DR

This study explores how cinnamomum cassia leaf extract may help treat ulcerative colitis by reducing inflammation and targeting key biological pathways.

## Contribution

The study identifies the anti-inflammatory mechanisms of cinnamomum cassia leaf extract in ulcerative colitis using network pharmacology and in vitro experiments.

## Key findings

- CCLE reduced nitric oxide and reactive oxygen species production in LPS-stimulated macrophages.
- CCLE inhibited macrophage migration and showed high binding affinity to key inflammatory targets.
- CCLE's effects are linked to pathways like PI3K-Akt, NF-κB, and TNF signaling.

## Abstract

Cinnamomum cassia essential oil production generates substantial waste, and the therapeutic potential of non-volatile constituents from cinnamomum cassia leaves in ulcerative colitis (UC) has not been fully explored. This research focused on identifying the principal components of cinnamomum cassia leaf extract (CCLE) through ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS), and its anti-inflammatory potential was verified in vitro. A lipopolysaccharide (LPS)-stimulated RAW264.7 macrophage model was employed, with assessments performed through cell viability assays, Griess assay, fluorescent probe detection, wound healing, and Transwell migration assays. Network pharmacology analysis combined with molecular docking revealed that CCLE exerts therapeutic effects against UC by targeting key molecules including TNF, TLR4, STAT3, SRC, PTGS2, NFKB1, MMP9, EGFR, BCL2, and AKT1, with high binding affinity between these targets and CCLE components (especially Quercetin, Catechin, Naringenin, 3′,4′-dimethoxyflavonol, Procyanidin Bl, and Caffeic acid). Enrichment analysis indicated that the therapeutic effect of CCLE on UC was significantly associated with the PI3K-Akt signaling pathway, B cell receptor signaling pathway, NF-κB signaling pathway, TNF signaling pathway, and JAK-STAT signaling pathway. The experimental results demonstrated that CCLE markedly reduced the production of nitric oxide (NO) and reactive oxygen species (ROS) (* p < 0.05) and inhibited macrophage migration (* p < 0.05). In conclusion, CCLE appears to ameliorate UC via a multi-target regulatory mechanism involving inflammatory signaling pathways. These outcomes offer a scientific foundation for the further development of CCLE.

## Linked entities

- **Proteins:** TNF (tumor necrosis factor), TLR4 (toll like receptor 4), STAT3 (signal transducer and activator of transcription 3), SRC (SRC proto-oncogene, non-receptor tyrosine kinase), PTGS2 (prostaglandin-endoperoxide synthase 2), NFKB1 (nuclear factor kappa B subunit 1), MMP9 (matrix metallopeptidase 9), EGFR (epidermal growth factor receptor), BCL2 (BCL2 apoptosis regulator), AKT1 (AKT serine/threonine kinase 1)
- **Chemicals:** Quercetin (PubChem CID 5280343), Catechin (PubChem CID 1203), Naringenin (PubChem CID 932), 3′,4′-dimethoxyflavonol (PubChem CID 97143), Caffeic acid (PubChem CID 689043), nitric oxide (PubChem CID 145068)
- **Diseases:** ulcerative colitis (MONDO:0005101)

## Full-text entities

- **Genes:** STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}
- **Diseases:** inflammatory (MESH:D007249), UC (MESH:D003093)
- **Chemicals:** Catechin (MESH:D002392), Caffeic acid (MESH:C040048), NO (MESH:D009569), 3',4'-dimethoxyflavonol (-), LPS (MESH:D008070), Quercetin (MESH:D011794), ROS (MESH:D017382), Naringenin (MESH:C005273)
- **Species:** Cinnamomum aromaticum (species) [taxon 119260]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12986900/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12986900/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12986900/full.md

---
Source: https://tomesphere.com/paper/PMC12986900